Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arrowhead Pharmaceuticals Inc ARWR

Healthcare Biotechnology
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform... see more

Recent & Breaking News (NDAQ:ARWR)

Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome

Business Wire January 12, 2022

Arrowhead Initiates Project to Build New Manufacturing and Lab Facilities

Business Wire December 20, 2021

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Business Wire December 17, 2021

Direxion Launches mRNA ETF (MSGR)

PR Newswire December 9, 2021

Arrowhead Pharmaceuticals to Participate in Upcoming December 2021 Conferences

Business Wire November 30, 2021

Arrowhead Pharmaceuticals Reports Fiscal 2021 Year End Results

Business Wire November 22, 2021

Arrowhead Pharmaceuticals Enters Exclusive License Agreement with GSK for ARO-HSD

Business Wire November 22, 2021

Arrowhead Announces JNJ-75220795 in Development for NASH

Business Wire November 17, 2021

Arrowhead Collaborator Presents Phase 2b Clinical Data from REEF-1 Study in Patients with Chronic Hepatitis B Infection

Business Wire November 15, 2021

Arrowhead Presents New Clinical Data on ARO-APOC3 at AHA 2021

Business Wire November 15, 2021

Arrowhead Presents Additional Clinical Data on Investigational ARO-HSD Treatment at AASLD Liver Meeting

Business Wire November 12, 2021

Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment at AASLD Liver Meeting

Business Wire November 12, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Year End Results

Business Wire November 1, 2021

Arrowhead Pharmaceuticals to Participate in Upcoming November 2021 Conferences

Business Wire November 1, 2021

Arrowhead Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-C3 for Treatment of Complement Mediated Diseases

Business Wire October 25, 2021

Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-C3 for Treatment of Complement Mediated Diseases

Business Wire October 12, 2021

Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia

Business Wire September 30, 2021

Arrowhead Pharmaceuticals to Participate in Upcoming October 2021 Conferences

Business Wire September 29, 2021

Arrowhead Earns $10 Million Phase 1 Milestone Payment

Business Wire September 28, 2021

Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences

Business Wire September 1, 2021